We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
- Authors
Miyoshi, M; Mizuno, M; Ishiki, K; Nagahara, Y; Maga, T; Torigoe, T; Nasu, J; Okada, H; Yokota, K; Oguma, K; Tsuji, T
- Abstract
The genetic polymorphism of cytochrome P450 (CYP) 2C19 has been shown to influence the efficacy of Helicobacter pylori eradication therapy with a proton pump inhibitor (PPI) and amoxicillin (so-called dual therapy). Omeprazole, a widely used PPI, and rabeprazole, a new PPI, are metabolized in different pathways in terms of CYP2C19 genetic polymorphisms. In this study, we compared the efficacy of omeprazole and rabeprazole in a 2-week dual therapy in relation to CYP2C19 polymorphism.
- Publication
Journal of gastroenterology and hepatology, 2001, Vol 16, Issue 7, p723
- ISSN
0815-9319
- Publication type
Journal Article
- DOI
10.1046/j.1440-1746.2001.02526.x